Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters

被引：84
|
作者：
Brauch, Hiltrud [1 ,2 ]
Schroth, Werner [1 ,2 ]
Goetz, Matthew P. [3 ]
Muerdter, Thomas E. [1 ,2 ]
Winter, Stefan [1 ,2 ]
Ingle, James N. [3 ]
Schwab, Matthias [1 ,2 ,4 ]
Eichelbaum, Michel [1 ,2 ]
机构：
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Mayo Clin, Rochester, MN USA
[4] Univ Tubingen Hosp, Inst Expt & Clin Pharmacol & Toxicol, Tubingen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 02期
关键词：
GROUP; 1-98; TRIAL; METABOLITE PLASMA-CONCENTRATIONS; REUPTAKE INHIBITOR PAROXETINE; ESTROGEN-RECEPTOR; ACTIVE METABOLITE; RE CYP2D6; ADJUVANT TAMOXIFEN; UGT2B7; GENOTYPE; WOMEN; POLYMORPHISMS;
D O I：
10.1200/JCO.2012.44.6625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：176 / 180
页数：5
相关论文
共 50 条
  • [1] CYP2D6 and tamoxifen: DNA matters in breast cancer
    Hoskins, Janelle M.
    Carey, Lisa A.
    Mcleod, Howard L.
    NATURE REVIEWS CANCER, 2009, 9 (08) : 576 - 586
  • [2] CYP2D6 and tamoxifen: DNA matters in breast cancer
    Janelle M. Hoskins
    Lisa A. Carey
    Howard L. McLeod
    Nature Reviews Cancer, 2009, 9 : 576 - 586
  • [3] CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Berry, Donald
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17): : 1267 - 1269
  • [4] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Province, Michael A.
    Klein, Teri E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [5] CYP2D6 GENOTYPING TO GUIDE USE OF TAMOXIFEN IN BREAST CANCER
    Irvin, William J., Jr.
    Weck, Karen E.
    Walko, Christine M.
    Ibrahim, Joseph G.
    Chiu, Wing. K.
    Dees, E. Claire
    Ogburn, Evan T.
    Desta, Zeruesenay
    Flockhart, David A.
    McLeod, Howard L.
    Evans, James P.
    Carey, Lisa A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S88 - S88
  • [6] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer Response
    Berry, Donald A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [7] Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
    Carmen W. H. Chan
    Bernard M. H. Law
    Winnie K. W. So
    Ka Ming Chow
    Mary M. Y. Waye
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1395 - 1404
  • [8] CYP2D6 tamoxifen: Pharmacogenetics in early breast cancer
    Brauch H.
    Schroth W.
    Der Gynäkologe, 2010, 43 (7): : 579 - 585
  • [9] Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
    Chan, Carmen W. H.
    Law, Bernard M. H.
    So, Winnie K. W.
    Chow, Ka Ming
    Waye, Mary M. Y.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1395 - 1404
  • [10] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Laurent Azoulay
    Sophie Dell’Aniello
    Laetitia Huiart
    Guillaume Galbaud du Fort
    Samy Suissa
    Breast Cancer Research and Treatment, 2011, 126 : 695 - 703
12345